411 results on '"Wolf, Dieter A"'
Search Results
2. CD11b is a therapy resistance– and minimal residual disease–specific marker in precursor B-cell acute lymphoblastic leukemia
- Author
-
Rhein, Peter, Mitlohner, Rita, Basso, Giuseppe, Gaipa, Giuseppe, Dworzak, Michael N., Kirschner-Schwabe, Renate, Hagemeier, Christian, Stanulla, Martin, Schrappe, Martin, Ludwig, Wolf-Dieter, Karawajew, Leonid, and Ratei, Richard
- Published
- 2010
- Full Text
- View/download PDF
3. Molecular response to treatment redefines all prognostic factors in children and adolescents with B-cell precursor acute lymphoblastic leukemia: results in 3184 patients of the AIEOP-BFM ALL 2000 study
- Author
-
Conter, Valentino, Bartram, Claus R., Valsecchi, Maria Grazia, Schrauder, André, Panzer-Grümayer, Renate, Möricke, Anja, Aricò, Maurizio, Zimmermann, Martin, Mann, Georg, De Rossi, Giulio, Stanulla, Martin, Locatelli, Franco, Basso, Giuseppe, Niggli, Felix, Barisone, Elena, Henze, Günter, Ludwig, Wolf-Dieter, Haas, Oskar A., Cazzaniga, Giovanni, Koehler, Rolf, Silvestri, Daniela, Bradtke, Jutta, Parasole, Rosanna, Beier, Rita, van Dongen, Jacques J.M., Biondi, Andrea, and Schrappe, Martin
- Published
- 2010
- Full Text
- View/download PDF
4. Dose-dense induction with sequential high-dose cytarabine and mitoxantone (S-HAM) and pegfilgrastim results in a high efficacy and a short duration of critical neutropenia in de novo acute myeloid leukemia: a pilot study of the AMLCG
- Author
-
Braess, Jan, Spiekermann, Karsten, Staib, Peter, Grüneisen, Andreas, Wörmann, Bernhard, Ludwig, Wolf-Dieter, Serve, Hubert, Reichle, Albrecht, Peceny, Rudolf, Oruzio, Daniel, Schmid, Christoph, Schiel, Xaver, Hentrich, Marcus, Sauerland, Christina, Unterhalt, Michael, Fiegl, Michael, Kern, Wolfgang, Buske, Christian, Bohlander, Stefan, Heinecke, Achim, Baurmann, Herrad, Beelen, Dietrich W., Berdel, Wolfgang E., Büchner, Thomas, and Hiddemann, Wolfgang
- Published
- 2009
- Full Text
- View/download PDF
5. Molecular allelokaryotyping of pediatric acute lymphoblastic leukemias by high-resolution single nucleotide polymorphism oligonucleotide genomic microarray
- Author
-
Kawamata, Norihiko, Ogawa, Seishi, Zimmermann, Martin, Kato, Motohiro, Sanada, Masashi, Hemminki, Kari, Yamatomo, Go, Nannya, Yasuhito, Koehler, Rolf, Flohr, Thomas, Miller, Carl W., Harbott, Jochen, Ludwig, Wolf-Dieter, Stanulla, Martin, Schrappe, Martin, Bartram, Claus R., and Koeffler, H. Phillip
- Published
- 2008
- Full Text
- View/download PDF
6. A new prognostic index (MIPI) for patients with advanced-stage mantle cell lymphoma
- Author
-
Hoster, Eva, Dreyling, Martin, Klapper, Wolfram, Gisselbrecht, Christian, van Hoof, Achiel, Kluin-Nelemans, Hanneke C., Pfreundschuh, Michael, Reiser, Marcel, Metzner, Bernd, Einsele, Hermann, Peter, Norma, Jung, Wolfram, Wörmann, Bernhard, Ludwig, Wolf-Dieter, Dührsen, Ulrich, Eimermacher, Hartmut, Wandt, Hannes, Hasford, Joerg, Hiddemann, Wolfgang, and Unterhalt, Michael
- Published
- 2008
- Full Text
- View/download PDF
7. Stress-induced activation of the p53 tumor suppressor in leukemia cells and normal lymphocytes requires mitochondrial activity and reactive oxygen species
- Author
-
Karawajew, Leonid, Rhein, Peter, Czerwony, Grit, and Ludwig, Wolf-Dieter
- Published
- 2005
- Full Text
- View/download PDF
8. The impact of the methotrexate administration schedule and dose in the treatment of children and adolescents with B-cell neoplasms: a report of the BFM Group Study NHL-BFM95
- Author
-
Woessmann, Wilhelm, Seidemann, Kathrin, Mann, Georg, Zimmermann, Martin, Burkhardt, Birgit, Oschlies, Ilske, Ludwig, Wolf-Dieter, Klingebiel, Thomas, Graf, Norbert, Gruhn, Bernd, Juergens, Heribert, Niggli, Felix, Parwaresch, Reza, Gadner, Helmut, Riehm, Hansjoerg, Schrappe, Martin, and Reiter, Alfred
- Published
- 2005
- Full Text
- View/download PDF
9. In vitro susceptibility to dexamethasone- and doxorubicin-induced apoptotic cell death in context of maturation stage, responsiveness to interleukin 7, and early cytoreduction in vivo in childhood T-cell acute lymphoblastic leukemia
- Author
-
Wuchter, Christian, Ruppert, Velia, Schrappe, Martin, Dörken, Bernd, Ludwig, Wolf-Dieter, and Karawajew, Leonid
- Published
- 2002
- Full Text
- View/download PDF
10. Inhibition of in vitro spontaneous apoptosis by IL-7 correlates with Bcl-2 up-regulation, cortical/mature immunophenotype, and better early cytoreduction of childhood T-cell acute lymphoblastic leukemia
- Author
-
Karawajew, Leonid, Ruppert, Velia, Wuchter, Christian, Kösser, Annett, Schrappe, Martin, Dörken, Bernd, and Ludwig, Wolf-Dieter
- Published
- 2000
- Full Text
- View/download PDF
11. Intensive ALL-type therapy without local radiotherapy provides a 90% event-free survival for children with T-cell lymphoblastic lymphoma: a BFM Group report
- Author
-
Reiter, Alfred, Schrappe, Martin, Ludwig, Wolf-Dieter, Tiemann, Markus, Parwaresch, Reza, Zimmermann, Martin, Schirg, Eckard, Henze, Günter, Schellong, Günther, Gadner, Helmut, and Riehm, Hansjörg
- Published
- 2000
- Full Text
- View/download PDF
12. Improved Treatment Results in Childhood B-Cell Neoplasms With Tailored Intensification of Therapy: A Report of the Berlin-Frankfurt-Mu¨nster Group Trial NHL-BFM 90
- Author
-
Reiter, Alfred, Schrappe, Martin, Tiemann, Markus, Ludwig, Wolf-Dieter, Yakisan, Elif, Zimmermann, Martin, Mann, Georg, Chott, Andreas, Ebell, Wolfram, Klingebiel, Thomas, Graf, Norbert, Kremens, Bernhard, Mu¨ller-Weihrich, Stefan, Plu¨ss, Hans-Ju¨rgen, Zintl, Felix, Henze, Gu¨nter, and Riehm, Hansjo¨rg
- Published
- 1999
- Full Text
- View/download PDF
13. Prednisone Response Is the Strongest Predictor of Treatment Outcome in Infant Acute Lymphoblastic Leukemia
- Author
-
Dördelmann, Michael, Reiter, Alfred, Borkhardt, Arndt, Ludwig, Wolf-Dieter, Götz, Nicolai, Viehmann, Susanne, Gadner, Helmut, Riehm, Hansjörg, and Schrappe, Martin
- Published
- 1999
- Full Text
- View/download PDF
14. Double Induction Strategy for Acute Myeloid Leukemia: The Effect of High-Dose Cytarabine With Mitoxantrone Instead of Standard-Dose Cytarabine With Daunorubicin and 6-Thioguanine: A Randomized Trial by the German AML Cooperative Group
- Author
-
Büchner, Thomas, Hiddemann, Wolfgang, Wörmann, Bernhard, Löffler, Helmut, Gassmann, Winfried, Haferlach, Torsten, Fonatsch, Christa, Haase, Detlef, Schoch, Claudia, Hossfeld, Dieter, Lengfelder, Eva, Aul, Carlo, Heyll, Axel, Maschmeyer, Georg, Ludwig, Wolf-Dieter, Sauerland, Maria-Cristina, and Heinecke, Achim
- Published
- 1999
- Full Text
- View/download PDF
15. Mixed-phenotype acute leukemia: clinical and laboratory features and outcome in 100 patients defined according to the WHO 2008 classification
- Author
-
Alberto Orfao, Winfried F. Pickl, Ricardo Morilla, John Swansbury, Marie C. Béné, Herbert Strobl, Sue Ashley, Estella Matutes, Georg Hopfinger, Petr Lemez, Mars B. van 't Veer, Richard Schabath, Andishe Attarbaschi, Wolf-Dieter Ludwig, and Anna Porwit
- Subjects
Adult ,Male ,medicine.medical_specialty ,Pathology ,Myeloid ,Adolescent ,Combination therapy ,T-Lymphocytes ,Immunology ,World Health Organization ,Biochemistry ,Gastroenterology ,Immunophenotyping ,hemic and lymphatic diseases ,Internal medicine ,medicine ,Humans ,Cell Lineage ,B-Lymphocytes ,Acute leukemia ,Hematology ,business.industry ,Infant ,Myeloid leukemia ,Cell Differentiation ,Imatinib ,Cell Biology ,Precursor Cell Lymphoblastic Leukemia-Lymphoma ,Flow Cytometry ,Transplantation ,Treatment Outcome ,medicine.anatomical_structure ,Cytogenetic Analysis ,Female ,Blast Crisis ,business ,medicine.drug - Abstract
The features of 100 mixed-phenotype acute leukemias (MPALs), fulfilling WHO 2008 criteria, are documented. Myeloid and T-lineage features were demonstrated by cytoplasmic myeloperoxidase and CD3; B-lineage features were demonstrated by at least 2 B-lymphoid markers. There were 62 men and 38 women; 68% were adults. Morphology was consistent with acute lymphoblastic leukemia (ALL; 43%), acute myeloid leukemia (AML; 42%), or inconclusive (15%). Immunophenotyping disclosed B + myeloid (59%), T + myeloid (35%), B + T (4%), or trilineage (2%) combinations. Cytogenetics evidenced t(9;22)/(Ph+) (20%), 11q23/ MLL rearrangements (8%), complex (32%), aberrant (27%), or normal (13%) karyotypes. There was no correlation between age, morphology, immunophenotype, or cytogenetics. Response to treatment and outcome were available for 67 and 70 patients, respectively; 27 received ALL, 34 AML, 5 a combination of ALL + AML therapy, and 1 imatinib. ALL treatment induced a response in 85%, AML therapy in 41%; 3 of 5 patients responded to the combination therapy. Forty (58%) patients died, 33 of resistant disease. Overall median survival was 18 months and 37% of patients are alive at 5 years. Age, Ph+, and AML therapy were predictors for poor outcome (P < .001; P = .002; P = .003). MPAL is confirmed to be a poor-risk disease. Adults and Ph+ patients should be considered for transplantation in first remission.
- Published
- 2011
16. Molecular response to treatment redefines all prognostic factors in children and adolescents with B-cell precursor acute lymphoblastic leukemia: results in 3184 patients of the AIEOP-BFM ALL 2000 study
- Author
-
Georg Mann, Giuseppe Basso, Maurizio Aricò, Daniela Silvestri, Guenter Henze, Jacques J.M. van Dongen, Martin Zimmermann, Rita Beier, Felix Niggli, Claus R. Bartram, Franco Locatelli, Elena Barisone, Oskar A. Haas, Andrea Biondi, Maria Grazia Valsecchi, Valentino Conter, Anja Möricke, Wolf-Dieter Ludwig, Rolf Koehler, Martin Stanulla, Renate Panzer-Grümayer, Rosanna Parasole, Martin Schrappe, André Schrauder, Giulio Rossi, Giovanni Cazzaniga, Jutta Bradtke, Conter, V, Bartram, C, Valsecchi, M, Schrauder, A, Panzer Grumayer, R, Moricke, A, Arico, M, Zimmermann, M, Mann, G, De Rossi, G, Stanulla, M, Locatelli, F, Basso, G, Niggli, F, Barisone, E, Henze, G, Ludwig, W, Haas, O, Cazzaniga, G, Koehler, R, Silvestri, D, Bradtke, J, Parasole, R, Beier, R, van Dongen, J, Biondi, A, Schrappe, M, University of Zurich, and Immunology
- Subjects
Oncology ,Pediatrics ,Neoplasm, Residual ,1303 Biochemistry ,2720 Hematology ,Kaplan-Meier Estimate ,Biochemistry ,1307 Cell Biology ,Prednisone ,hemic and lymphatic diseases ,Antineoplastic Combined Chemotherapy Protocols ,Genotype ,Medicine ,Child ,Gene Rearrangement, B-Lymphocyte ,Prospective cohort study ,Reverse Transcriptase Polymerase Chain Reaction ,Remission Induction ,Hematology ,Precursor Cell Lymphoblastic Leukemia-Lymphoma ,Prognosis ,Treatment Outcome ,Real-time polymerase chain reaction ,medicine.anatomical_structure ,Child, Preschool ,medicine.drug ,medicine.medical_specialty ,Adolescent ,Immunology ,Receptors, Antigen, T-Cell ,Receptors, Antigen, B-Cell ,610 Medicine & health ,Gene Rearrangement, T-Lymphocyte ,Disease-Free Survival ,Internal medicine ,White blood cell ,Biomarkers, Tumor ,Humans ,Children, adolescents, acute lymphoblastic leukemia ,B cell ,2403 Immunology ,business.industry ,Infant ,Cell Biology ,Minimal residual disease ,body regions ,Standard error ,10036 Medical Clinic ,business - Abstract
The Associazione Italiana di Ematologia Oncologia Pediatrica and the Berlin-Frankfurt-Münster Acute Lymphoblastic Leukemia (AIEOP-BFM ALL 2000) study has for the first time introduced standardized quantitative assessment of minimal residual disease (MRD) based on immunoglobulin and T-cell receptor gene rearrangements as polymerase chain reaction targets (PCR-MRD), at 2 time points (TPs), to stratify patients in a large prospective study. Patients with precursor B (pB) ALL (n = 3184) were considered MRD standard risk (MRD-SR) if MRD was already negative at day 33 (analyzed by 2 markers, with a sensitivity of at least 10-4); MRD high risk (MRD-HR) if 10-3 or more at day 78 and MRD intermediate risk (MRD-IR): others. MRD-SR patients were 42% (1348): 5-year event-free survival (EFS, standard error) is 92.3% (0.9). Fifty-two percent (1647) were MRD-IR: EFS 77.6% (1.3). Six percent of patients (189) were MRD-HR: EFS 50.1% (4.1; P < .001). PCR-MRD discriminated prognosis even on top of white blood cell count, age, early response to prednisone, and genotype. MRD response detected by sensitive quantitative PCR at 2 predefined TPs is highly predictive for relapse in childhood pB-ALL. The study is registered at http://clinicaltrials.gov: NCT00430118 for BFM and NCT00613457 for AIEOP. (Blood. 2010;115(16):3206-3214) © 2010 by The American Society of Hematology.
- Published
- 2010
17. Intact apoptosis signaling in myeloid leukemia cells determines treatment outcome in childhood AML
- Author
-
Dirk Reinhardt, Karsten Stahnke, Leonid Karawajew, SM Eckhoff, Klaus-Michael Debatin, Wolf-Dieter Ludwig, Lüder Hinrich Meyer, Manon Queudeville, and Ursula Creutzig
- Subjects
medicine.medical_specialty ,Myeloid ,Immunology ,Apoptosis ,Biochemistry ,Disease-Free Survival ,Risk Factors ,Internal medicine ,medicine ,Humans ,Child ,Childhood Acute Lymphoblastic Leukemia ,Hematology ,Caspase 3 ,business.industry ,Remission Induction ,Cytochromes c ,Myeloid leukemia ,Cell Biology ,medicine.disease ,Enzyme Activation ,Leukemia, Myeloid, Acute ,Leukemia ,Treatment Outcome ,medicine.anatomical_structure ,Cancer research ,Apoptosome ,business ,Signal Transduction ,Chronic myelogenous leukemia - Abstract
Recently we reported that intact apoptosis signaling is indicative of favorable outcome in childhood acute lymphoblastic leukemia. Here we addressed this issue in 45 pediatric acute myeloid leukemia patients analyzing 2 core apoptogenic events: cytochrome c release and caspase-3 activation. In patients with good prognosis cytochrome c release was clearly found to be caspasedependent and correlated with activated caspase-3, indicating that activation of initiator or amplifier caspases such as caspase-8 together with an intact apoptosome function are elementary for favorable outcome. The functional integrity of this apoptogenic checkpoint is reflected by the parameter caspase-dependent cytochrome c-related activation of caspase-3 (CRACdep). Patients with positive CRACdep values (intact signaling) exhibited superior survival compared with CRACdep negative patients (deficient signaling). Thus, the propensity to undergo apoptosis of leukemia cells is an important feature for favorable treatment outcome and may serve as an additional stratification tool for pediatric AML patients. This trial was registered at www.ClinicalTrials.gov as #NCT00111345.
- Published
- 2008
18. A new prognostic index (MIPI) for patients with advanced-stage mantle cell lymphoma
- Author
-
Wolfgang Hiddemann, Joerg Hasford, Wolf-Dieter Ludwig, Hartmut Eimermacher, Ulrich Dührsen, Bernd Metzner, Wolfram Klapper, Michael Pfreundschuh, Achiel Van Hoof, Norma Peter, Christian Gisselbrecht, H. Einsele, Hannes Wandt, Wolfram Jung, Martin Dreyling, Marcel Reiser, Bernhard Wörmann, Eva Hoster, Michael Unterhalt, and Hanneke C. Kluin-Nelemans
- Subjects
Male ,Oncology ,Pathology ,Follicular lymphoma ,Lymphoma, Mantle-Cell ,IMPROVES RESPONSE ,Biochemistry ,Leukocyte Count ,0302 clinical medicine ,International Prognostic Index ,hemic and lymphatic diseases ,CYCLOPHOSPHAMIDE ,Medicine ,Randomized Controlled Trials as Topic ,Age Factors ,Hematology ,3. Good health ,Survival Rate ,EUROPEAN-MCL-NETWORK ,030220 oncology & carcinogenesis ,SURVIVAL ,Refractory Mantle Cell Lymphoma ,Regression Analysis ,Female ,PROSPECTIVE RANDOMIZED-TRIAL ,medicine.medical_specialty ,Immunology ,Disease-Free Survival ,CLASSIFICATION ,03 medical and health sciences ,Predictive Value of Tests ,Internal medicine ,REGRESSION ,Biomarkers, Tumor ,Humans ,NON-HODGKINS-LYMPHOMA ,Survival rate ,Cell Proliferation ,Neoplasm Staging ,Biologic marker ,L-Lactate Dehydrogenase ,Performance status ,business.industry ,CLINICAL-FEATURES ,Large cell ,RESIDUALS ,Cell Biology ,medicine.disease ,Mantle cell lymphoma ,business ,030215 immunology - Abstract
There is no generally established prognostic index for patients with mantle cell lymphoma (MCL), because the International Prognostic Index (IPI) and Follicular Lymphoma International Prognostic Index (FLIPI) have been developed for diffuse large cell and follicular lymphoma patients, respectively. Using data of 455 advanced stage MCL patients treated within 3 clinical trials, we examined the prognostic relevance of IPI and FLIPI and derived a new prognostic index (MCL international prognostic index, MIPI) of overall survival (OS). Statistical methods included Kaplan-Meier estimates and the log-rank test for evaluating IPI and FLIPI and multiple Cox regression for developing the MIPI. IPI and FLIPI showed poor separation of survival curves. According to the MIPI, patients were classified into low risk (44% of patients, median OS not reached), intermediate risk (35%, 51 months), and high risk groups (21%, 29 months), based on the 4 independent prognostic factors: age, performance status, lactate dehydrogenase (LDH), and leukocyte count. Cell proliferation (Ki-67) was exploratively analyzed as an important biologic marker and showed strong additional prognostic relevance. The MIPI is the first prognostic index particularly suited for MCL patients and may serve as an important tool to facilitate risk-adapted treatment decisions in patients with advanced stage MCL.
- Published
- 2008
19. T/NK-Cell Immunophenotype with Coexpression of CD56 Predicts Poor Outcome in Childhood T-ALL. Results of the ALL-BFM 2000 Trial
- Author
-
Fuhrmann, Stephan, primary, Karawajew, Leonid, additional, Schabath, Richard, additional, Moricke, Anja, additional, Zimmermann, Martin, additional, Ludwig, Wolf-Dieter, additional, Schrappe, Martin, additional, and Ratei, Richard, additional
- Published
- 2016
- Full Text
- View/download PDF
20. Cytochrome c–related caspase-3 activation determines treatment response and relapse in childhood precursor B-cell ALL
- Author
-
Leonid Karawajew, Karsten Stahnke, Martin Schrappe, Klaus-Michael Debatin, Lüder Hinrich Meyer, and Wolf-Dieter Ludwig
- Subjects
Adolescent ,Immunology ,Apoptosis ,Cell Count ,Caspase 3 ,Pharmacology ,Risk Assessment ,Biochemistry ,Recurrence ,Precursor B-Cell Lymphoblastic Leukemia-Lymphoma ,Acute lymphocytic leukemia ,Humans ,Medicine ,Child ,B cell ,Caspase ,Acute leukemia ,biology ,business.industry ,Cytochrome c ,Cytochromes c ,Infant ,Cell Biology ,Hematology ,Precursor Cell Lymphoblastic Leukemia-Lymphoma ,Flow Cytometry ,Prognosis ,medicine.disease ,Leukemia ,Treatment Outcome ,medicine.anatomical_structure ,Caspases ,Child, Preschool ,biology.protein ,business - Abstract
Deficient activation of apoptosis signaling pathways may be responsible for treatment failure in acute leukemia. Here, we address the impact of intact apoptosis signaling in 78 patients with pediatric precursor B-cell acute lymphoblastic leukemia (ALL) by analysis of 2 key apoptogenic events: caspase-3 activation and cytochrome c release in leukemia cells cultured in vitro. Both events correlated only in the group of patients who had a good response and patients in continuous remission, suggesting that intact apoptosis signaling is a characteristic for favorable outcome. By combining both parameters, we identified a novel indicator, cytochrome c–related activation of caspase-3 (CRAC). CRAC directly connects the extent of caspase-3 activation to cytochrome c release in single cells in an individual patient sample. In CRAC-positive patients, indicating proficient apoptosis signaling, the number of persisting leukemia cells on day 15 was significantly lower than in the CRAC-negative patient group (n = 27, mean 6.0% versus n = 36, mean 22.6%; P = .003). At a median follow-up of 31 months, disease-free survival was 84 months (95% CI = 76 to 91 months) and 66 months (95% CI = 52 to 80 months) for patients with positive and negative CRAC, respectively (P = .019). CRAC may serve as a functionally defined risk factor for treatment stratification.
- Published
- 2006
21. Stress-induced activation of the p53 tumor suppressor in leukemia cells and normal lymphocytes requires mitochondrial activity and reactive oxygen species
- Author
-
Leonid Karawajew, Wolf-Dieter Ludwig, Peter Rhein, and Grit Czerwony
- Subjects
Time Factors ,Oligomycin ,T-Lymphocytes ,Apoptosis ,Mitochondrion ,Biochemistry ,Membrane Potentials ,chemistry.chemical_compound ,Adenosine Triphosphate ,Lymphocytes ,Phosphorylation ,Cells, Cultured ,Thenoyltrifluoroacetone ,Chelating Agents ,Etoposide ,Oligonucleotide Array Sequence Analysis ,chemistry.chemical_classification ,Membrane potential ,Genome ,Hematology ,Flow Cytometry ,Mitochondria ,Up-Regulation ,Cell biology ,Gene Expression Regulation, Neoplastic ,Leukemia ,Intracellular ,Immunology ,Down-Regulation ,Electrons ,Biology ,Cell Line, Tumor ,Rotenone ,medicine ,Humans ,Reactive oxygen species ,Uncoupling Agents ,Intracellular Membranes ,Cell Biology ,medicine.disease ,Oxygen ,Oxidative Stress ,chemistry ,Drug Resistance, Neoplasm ,Mutation ,Oligomycins ,Tumor Suppressor Protein p53 ,Reactive Oxygen Species ,Adenosine triphosphate - Abstract
The p53 system is highly stress sensitive and integrates diverse intracellular signals in a complex and poorly defined manner. We report on the high dependence of stress-induced p53 activation on mitochondrial activity. Down-regulation of mitochondrial transmembrane potential (MTMP) by inhibitors of electron transport (rotenone, thenoyltrifluoroacetone (TTFA)) and adenosine triphosphate (ATP) synthesis (oligomycin) prevented stress-induced p53 protein accumulation and abrogated p53-dependent apoptosis in a wild-type p53 leukemia cell line MOLT-3, in primary leukemia cells and in normal T lymphocytes. Using genome-wide gene expression analysis, stress-induced up-regulation of the p53 transcriptional targets and their specific inhibition by oligomycin has been demonstrated. Oligomycin did not impair p53-independent apoptosis and caused only a slight reduction of intracellular ATP levels. Reactive oxygen species (ROS) localized to mitochondria decreased in the presence of oligomycin, and stress-induced p53 activation showed strong ROS sensitivity both in leukemic and normal cells. These observations identify mitochondrial activity, described by MTMP and ROS levels, as a critical intracellular determinant of the p53 stress sensitivity and suggest potential implications of this linkage in the mechanisms of chemoresistance of acute leukemia cells. (Blood. 2005;105:4767-4775)
- Published
- 2005
22. T/NK-Cell Immunophenotype with Coexpression of CD56 Predicts Poor Outcome in Childhood T-ALL. Results of the ALL-BFM 2000 Trial
- Author
-
Leonid Karawajew, Anja Möricke, Martin Schrappe, Wolf-Dieter Ludwig, Richard Ratei, Martin Zimmermann, Stephan Fuhrmann, and Richard Schabath
- Subjects
education.field_of_study ,medicine.medical_specialty ,Pathology ,Multivariate analysis ,business.industry ,Immunology ,Population ,Hazard ratio ,Cancer ,Cell Biology ,Hematology ,medicine.disease ,Biochemistry ,Gastroenterology ,Immunophenotyping ,Prednisone ,Internal medicine ,Cohort ,medicine ,Cumulative incidence ,education ,business ,medicine.drug - Abstract
Purpose: To investigate the prognostic impact of the coexpression of the natural killer cell marker CD56 / neural-cell adhesion molecule NCAM and to compare it to the immunophenotype subgroups according to the EGIL/WHO 2008 classification and to the early T-cell precursor (ETP) subtype for patients with T-ALL treated in the ALL-BFM 2000 protocol. Patients and Methods: The immunophenotype of 493 children with T-ALL was analyzed centrally at diagnosis with a four-color antibody panel consisting of 28 different antibodies for the detection of antigen expression in the cytoplasm and on the surface of the blast cell population. The frequency of immunophenotypic subtypes and their correlation with event-free survival (EFS) and cumulative incidence of relapse (CIR) were investigated. Results: The frequencies of T-ALL subtypes according to the EGIL/WHO classification were 0.4% for pro-T-ALL, 19.9% for pre-T-ALL, 64.7% for cortical T-ALL and 15% for mature T-ALL. The frequency of the ETP subtype according to the ETP-Score published by Inukai T. et al. (Br J Haematol. 2012) was 6.7% (surface CD3 negative) or 7.5% (with surface CD3 positivity) of all the patients with T-ALL. This is a lower frequency compared to the findings in the St. Jude and AIEOP patients published by Coustan-Smith E. et al. (Lancet Oncology 2009), but similar to what has been reported for the Tokyo Children's Cancer Study Group Study L99-15 by Inukai T. et al. (Br J Haematol. 2012). Coexpression of CD56 was detected in 7.2% of all T-ALL patients. The percentage of ETP in the CD56+ T-ALL cohort was 4-fold increased (30%) as compared to all T-ALL patients (7.2%). The 5-year EFS rates for the EGIL/WHO subgroups pre-T-ALL (n=57), cortical-T-ALL (n=310), and mature T-ALL (n=66) were not statistically different (0.72, SE=0.06, 0.83, SE=0.02, and 0.74, SE=0.06, respectively, Fig. 1). Also the 5-year EFS for the ETP (n=23) did not statistically differ from the non-ETP T-ALL cohort (Fig.1). By contrast, patients with CD56 coexpression (n=35) had a significantly lower 5-year EFS and a higher CIR at 5 years than patients without CD56-expression (EFS: 0.56, SE=0.09 vs. 0.80, SE=0.02, log-rank p = 0.001; CIR: 0.25, SE=0.8 vs. 0.14, SE=0.02, p(Gray) = 0.08), (Fig. 2). In the multivariate analysis, considering other risk parameters like age older than 10 years, WBC greater than 100,000 and prednisone response, CD56 coexpression was an independent prognostic marker for 5-year-EFS with a hazard ratio (HR) of 2.50 (p = 0.002). CD56 coexpression lost significant prognostic impact with the addition of the MRD risk groups to the multivariate model (HR=1.45, n.s.). Conclusion: In the ALL-BFM 2000 trial the prognostic significance of the ETP-phenotype, which has been previously demonstrated as being prognostically unfavorable in several ALL clinical trials, could not be confirmed. The CD56-coexpression, although not superior to the MRD risk assignment, warrants further investigation as an additional independent prognostic indicator at diagnosis for unfavorable clinical outcome in childhood T-ALL. Figure 1. T2=pre-T-ALL, T3=cortical, T4=mature, TNKP=CD56+ Figure 1. T2=pre-T-ALL, T3=cortical, T4=mature, TNKP=CD56+ Figure 2 T-ALL and CD56 coexpression Figure 2. T-ALL and CD56 coexpression Disclosures Moricke: JazzPharma: Honoraria, Other: financial support of travel costs.
- Published
- 2016
23. Inhibition of in vitro spontaneous apoptosis by IL-7 correlates with Bcl-2 up-regulation, cortical/mature immunophenotype, and better early cytoreduction of childhood T-cell acute lymphoblastic leukemia
- Author
-
Wolf-Dieter Ludwig, V. Ruppert, Leonid Karawajew, Martin Schrappe, Annett Kösser, Bernd Dörken, and Christian Wuchter
- Subjects
Programmed cell death ,Cell Survival ,CD3 ,Immunology ,Apoptosis ,Bone Marrow Cells ,Biochemistry ,Immunophenotyping ,Flow cytometry ,Bcl-2-associated X protein ,Proto-Oncogene Proteins ,Acute lymphocytic leukemia ,Humans ,Leukemia-Lymphoma, Adult T-Cell ,Medicine ,Receptors, Cytokine ,Child ,Cells, Cultured ,bcl-2-Associated X Protein ,biology ,medicine.diagnostic_test ,business.industry ,Interleukin-7 ,Cell Biology ,Hematology ,Precursor Cell Lymphoblastic Leukemia-Lymphoma ,Flow Cytometry ,medicine.disease ,Genes, bcl-2 ,Gene Expression Regulation ,Proto-Oncogene Proteins c-bcl-2 ,biology.protein ,Cancer research ,Interleukin-2 ,Interleukin-4 ,Blast Crisis ,business ,Cytokine receptor - Abstract
In normal T-cell development, IL-7 plays a nonredundant role as an antiapoptic factor by regulating Bcl-2 expression in pro-T cells. In the current study, we addressed the roles of IL-7 and related cytokines as apoptosis-modulating factors in precursor T-cell acute lymphoblastic leukemia (T-ALL). To this end, leukemic blasts from pediatric patients with T-ALL were prospectively investigated as to their responsiveness to IL-7, IL-4, and IL-2 (in terms of modulation of spontaneous apoptosis, assessed by flow cytometry), cytokine receptor expression profiles, and expression levels of Bcl-2 and Bax proteins. IL-7, in contrast to IL-4 and IL-2, was highly efficient in apoptosis inhibition , and this effect correlated with the expression levels of IL-7R chain and with the up-regulation of Bcl-2 protein expression (P< .0001). Subclassification of T-ALL samples (n = 130) according to their in vitro IL-7 responses revealed that IL-7 refractory samples were more frequently positive for CD34 (P< .0001) and the myeloid-associated antigen CD33 (P= .01), whereas IL-7 responsiveness was associated with an expression of more mature differentiation-associated T-cell antigens (CD1a, surface CD3, CD4/8; P < .05). Furthermore, the extent of apoptosis inhibition by IL-7 in vitro quantitatively correlated with early cytoreduction as determined by the prednisone peripheral blood response on day 8 and cytoreduction in the marrow on day 15 (n = 87;P < .05). Multivariate analysis of the apoptosis-related parameters investigated, including spontaneous apoptosis, its inhibition by IL-7, and expression levels of Bcl-2 and Bax, showed that only IL-7 responsiveness has an independent impact on early cytoreduction (P < .05), thus indicating a potential prognostic relevance of IL-7 sensitivity in T-ALL.
- Published
- 2000
24. CD95 (APO-1/Fas) Mutations in Childhood T-Lineage Acute Lymphoblastic Leukemia
- Author
-
Elke Kurz, Klaus-Michael Debatin, Wolf-Dieter Ludwig, Martin Schrappe, Christian Beltinger, and Thomas Böhler
- Subjects
Tumor suppressor gene ,Immunology ,chemical and pharmacologic phenomena ,hemic and immune systems ,Cell Biology ,Hematology ,Gene mutation ,Biology ,Fas receptor ,medicine.disease_cause ,medicine.disease ,Biochemistry ,biological factors ,Exon ,medicine.anatomical_structure ,hemic and lymphatic diseases ,Lymphocyte homeostasis ,Acute lymphocytic leukemia ,medicine ,Cancer research ,biological phenomena, cell phenomena, and immunity ,Carcinogenesis ,B cell - Abstract
CD95 (APO-1/Fas)-mediated apoptosis is pivotal in normal lymphocyte homeostasis and mutations of CD95 cause a benign autoimmune lymphoproliferation syndrome (ALPS) in humans and mice. However, tumors only rarely develop in these patients, and no CD95 mutations have yet been directly implicated in tumorigenesis. We therefore examined 81 de novo childhood T-lineage acute lymphoblastic leukemias (T-ALL) including 54 steroid-poor responders, 10 relapsed T-ALL, and 10 leukemic T-cell lines, for the presence of CD95 mutations using single-strand confirmation polymorphism and sequence analysis. In leukemic blasts and normal T cells of one patient, a heterozygous mutation in exon 3 of CD95 causing a 68Pro → 68Leu change associated with decreased CD95-mediated apoptosis was found. In leukemic blasts and normal T cells of a second patient, a homozygous mutation in the promoter of CD95 causing disruption of a consensus sequence for AP-2 binding without decreasing constitutive CD95 expression was detected. No large intragenic alterations of CD95 were found, no homozygous loss was detected in the cell lines, and no CD95 mutations were detected in the relapses. The data presented here show that CD95 mutations occur in some T-ALL and may be of biological importance.
- Published
- 1998
25. Transcript synthesis and surface expression of the interleukin-2 receptor (alpha-, beta-, and gamma-chain) by normal and malignant myeloid cells
- Author
-
HJ Gruss, Jerome Ritz, JC Renauld, M. A. Brach, Friedhelm Herrmann, C Kirschning, U von Arnim, T Nakarai, Wolf-Dieter Ludwig, Leonid Karawajew, and Ralf R. Schumann
- Subjects
medicine.medical_specialty ,Myeloid ,Janus kinase 3 ,Immunology ,Myeloid leukemia ,Cell Biology ,Hematology ,Biology ,medicine.disease ,Biochemistry ,Molecular biology ,Leukemia ,Endocrinology ,medicine.anatomical_structure ,Cell surface receptor ,Internal medicine ,medicine ,Myelopoiesis ,Signal transduction ,Interleukin-7 receptor - Abstract
Expression of the interleukin-2 receptor alpha-(IL-2Ralpha-), IL-2Rbeta- , and the recently identified IL-2Rgamma-chain was examined on a wide range of cells of myeloid origin including neutrophils, monocytes, normal bone marrow-derived myeloid progenitors enriched for CD34+ cells, bone marrow blasts obtained from acute myelogenous leukemia (AML) patients, and permanent myeloid leukemia cell lines by reverse transcriptase-polymerase chain reaction and surface membrane analysis using receptor chain-specific monoclonal antibodies and flow cytometry. Expression of the p75 IL-2Rbeta- and the p64 IL-2Rgamma-chain was a common finding in most of the myeloid cell samples investigated, whereas IL-2Ralpha-chain was less frequently expressed. Although the high-affinity IL-2R form (ie, the alpha+, beta+, gamma+ IL-2R form) was detectable in a small minority of primary AML samples as well as the KG- 1 cell line and IL-2 binding to these cells was sufficient to initiate signal transduction as evidenced by an increase in overall protein tyrosine phosphorylation and more specifically in tyrosine phosphorylation of the Janus kinase (JAK) 3, in none of these cell types did exposure to IL-2 affect cell growth kinetics. These results suggest that, in myeloid cells, the IL-2R may not stimulate mitogenic responses or that its components may be expressed in a combinational association with receptors for other cytokines and that IL-2Rgamma may play a regulatory role in normal and malignant myelopoiesis possibly independent from IL-2. Because recent studies by others have indicated that the IL-2Rgamma- chain may be shared by the IL-4R, the IL-7R, and most likely the IL-9R, expression of mRNA of these receptor types was also investigated in these cell samples. Surprisingly, in a substantial part of the myeloid lineage cells examined, an IL-2Rgamma+, IL-4R-, IL7R- configuration was noted that was, however, frequently associated with expression of IL-9R. Sharing of IL-9R/IL-2R components was furthermore suggested by inhibition of 125I-IL-2 binding to primary AML cells with excess of unlabeled IL-9.
- Published
- 1996
26. Clinical significance of surface antigen expression in children with acute myeloid leukemia: results of study AML-BFM-87
- Author
-
Martin Zimmermann, Günther Schellong, Wolf-Dieter Ludwig, Helmut Loffler, Christian Sperling, Jochen Harbott, Hansjörg Riehm, U. Creutzig, and Jörg Ritter
- Subjects
Adolescent ,Daunorubicin ,Immunology ,CD33 ,Sensitivity and Specificity ,Biochemistry ,Disease-Free Survival ,Immunophenotyping ,Antigen ,Antigens, CD ,Antigens, Neoplasm ,Predictive Value of Tests ,Antineoplastic Combined Chemotherapy Protocols ,Biomarkers, Tumor ,Humans ,Medicine ,Prospective Studies ,Child ,Etoposide ,Proportional Hazards Models ,Chromosome Aberrations ,Auer rod ,business.industry ,Childhood Acute Myeloid Leukemia ,Cytarabine ,Antibodies, Monoclonal ,Infant ,Myeloid leukemia ,Cell Biology ,Hematology ,Prognosis ,medicine.disease ,Combined Modality Therapy ,Leukemia ,Treatment Outcome ,Leukemia, Myeloid ,Child, Preschool ,Acute Disease ,Antigens, Surface ,Neoplastic Stem Cells ,Cranial Irradiation ,business ,medicine.drug - Abstract
Immunophenotyping using a panel of 15 antibodies was performed in 267 (87%) and cytogenetic analysis in 196 (64%) of 307 children under 17 years of age enrolled in the AML-BFM-87 study. Treatment consisted of cytosine arabinoside, daunorubicin, etoposide induction and a 6-week seven-drug consolidation chemotherapy, followed by two blocks of high-dose cytosine arabinoside with or without cranial irradiation and maintenance therapy for 1 year. Five-year event-free survival for patients with immunophenotypic data was .43 +/- .03 SE. The diagnostic value of the pan-myeloid reagents CD13, CD33, and CDw65 for the recognition of childhood acute myeloid leukemia (AML) was high with a sensitivity of 98% (positivity of at least one of these antigens), whereas, with the exception of CD41 for French American British (FAB) subtype M7, the expression of single cell-surface antigens showed no correlation with morphologic or cytogenetic subgroups. On the other hand, characteristic subgroups of AML defined by morphologic features and karyotypes could be described by low or high rates of surface antigen expression compared with those of other patients. These immunophenotypic features most probably associated with specific entities include expression of CD34 or CD13 and absence of CD14 or CD4 in M2 with Auer rods/t(8;21); absence of HLA-DR, CD34, and CD14, but expression of CD33 in M3/t(15;17); positivity of either CD34 or CD13 and either CD14 or CD2 for M4Eo/inv(16); and absence of either CD34 or CD13 and expression of either CD33 or CDw65 and either CD15 or CD4 for M5/t(9;11). In FAB M0, negativity of one or two of the three panmyeloid-associated markers (CD13/33/w65) was common; and cytogenetic results frequently showed random abnormalities. Expression of lymphoid-, progenitor- and most myeloid-associated antigens had no influence on the prognosis, whereas the outcome was significantly better for children with M2 with Auer rods, M3, or M4Eo or for those with the associated karyotypes t(8;21);t(15;17) and inv(16) than for other patients.
- Published
- 1995
27. Adult patients with acute lymphoblastic leukemia and molecular failure display a poor prognosis and are candidates for stem cell transplantation and targeted therapies
- Author
-
Stefan Schwartz, C. R. Bartram, Hubert Serve, Rainer Fietkau, Dieter Hoelzer, Mathias Freund, Nicola Gökbuget, Thorsten Raff, Renate Arnold, Georg Maschmeyer, Michael Kneba, Heiko Trautmann, Arnold Ganser, Monika Brüggemann, Harald Rieder, Eckhard Thiel, and Wolf-Dieter Ludwig
- Subjects
Oncology ,Adult ,medicine.medical_specialty ,Neoplasm, Residual ,Adolescent ,medicine.medical_treatment ,Immunology ,Hematopoietic stem cell transplantation ,Biochemistry ,Young Adult ,Internal medicine ,Acute lymphocytic leukemia ,medicine ,Humans ,Transplantation, Homologous ,Prospective Studies ,Prospective cohort study ,Survival analysis ,business.industry ,Remission Induction ,Hematopoietic Stem Cell Transplantation ,Consolidation Chemotherapy ,Cell Biology ,Hematology ,Induction Chemotherapy ,Middle Aged ,Precursor Cell Lymphoblastic Leukemia-Lymphoma ,medicine.disease ,Prognosis ,Minimal residual disease ,Combined Modality Therapy ,Survival Analysis ,Surgery ,Transplantation ,Treatment Outcome ,Molecular Response ,business - Abstract
Quantification of minimal residual disease (MRD) by real-time PCR directed to TCR and Ig gene rearrangements allows a refined evaluation of response in acute lymphoblastic leukemia (ALL). The German Multicenter Study Group for Adult ALL prospectively evaluated molecular response after induction/consolidation chemotherapy according to standardized methods and terminology in patients with Philadelphia chromosome-negative ALL. The cytologic complete response (CR) rate was 89% after induction phases 1 and 2. At this time point the molecular CR rate was 70% in 580 patients with cytologic CR and evaluable MRD. Patients with molecular CR after consolidation had a significantly higher probability of continuous complete remission (CCR; 74% vs 35%; P < .0001) and of overall survival (80% vs 42%; P = .0001) compared with patients with molecular failure. Patients with molecular failure without stem cell transplantation (SCT) in first CR relapsed after a median time of 7.6 months; CCR and survival at 5 years only reached 12% and 33%, respectively. Quantitative MRD assessment identified patients with molecular failure as a new high-risk group. These patients display resistance to conventional drugs and are candidates for treatment with targeted, experimental drugs and allogeneic SCT. Molecular response was shown to be highly predictive for outcome and therefore constitutes a relevant study end point. The studies are registered at www.clinicaltrials.gov as NCT00199056 and NCT00198991.
- Published
- 2012
28. Pre-pre-B acute lymphoblastic leukemia: high frequency of alternatively spliced ALL1-AF4 transcripts and absence of minimal residual disease during complete remission
- Author
-
R Repp, J. W. G. Janssen, H Rieder, C Fonatsch, DK Hossfeld, Wolf-Dieter Ludwig, Ansgar Schulz, U Spadinger, J. Harbott, and A Borkhardt
- Subjects
CD20 ,medicine.medical_specialty ,Immunology ,Cell Biology ,Hematology ,Gene rearrangement ,Pre-Pre-B Acute Lymphoblastic Leukemia ,Biology ,medicine.disease ,Biochemistry ,Minimal residual disease ,Gastroenterology ,CD19 ,Immunophenotyping ,Antigen ,hemic and lymphatic diseases ,Acute lymphocytic leukemia ,Internal medicine ,medicine ,biology.protein - Abstract
We used the polymerase chain reaction (PCR) to detect ALL1-AF4 rearrangements, the molecular hallmark of t(4;11) in a series of 46 pre- pre-B (CD19+, CD24+, CD10/CD20/cylgM/sIgM-) acute lymphoblastic leukemias (ALL). Eighteen patients (39%) exhibited fusion transcripts including 4 of 12 children and 14 of 34 adults. This genetic defect was associated with hyperleukocytosis (median leukocyte count 176 x 10(9)/L) and expression of myeloid-associated antigens (CDw65+). In contrast, only two patients from a group of 67 common (CD19/CD10+, cylgM/sIgM-) and pre-B ALLs (CD19/cylgM+, CD10 +/-, sIgM-) showed ALL1- AF4 mRNA. All PCR-positive cases showed multiple amplification products representing alternative splicing events. Moreover, reciprocal der (4)- derived AF4-ALL1 transcripts were observed in 65% of the cases analyzed. Eight of the 18 pre-pre-B ALL patients with an ALL1-AF4 recombination are currently in complete continuous remission for up to 54 months (median, 26 months). Twelve remission samples were available from seven cases, and all of them lacked evidence of minimal residual disease. Overall this study documents a similarly high incidence of ALL1-AF4 recombinations in children (infants excluded) and adults with pre-pre-B ALL and demonstrates the decline of the leukemic cell clone below the detection level of PCR in a remarkable proportion of patients under intense treatment protocols.
- Published
- 1994
29. Chemotherapy in 998 unselected childhood acute lymphoblastic leukemia patients. Results and conclusions of the multicenter trial ALL-BFM 86
- Author
-
S Sauter, W Havers, Martin Schrappe, W Hiddemann, Martin Zimmermann, G Henze, Alfred Reiter, F Lampert, D Niethammer, and Wolf-Dieter Ludwig
- Subjects
medicine.medical_specialty ,Chemotherapy ,Mitoxantrone ,Ifosfamide ,business.industry ,medicine.medical_treatment ,Immunology ,Cell Biology ,Hematology ,Biochemistry ,Gastroenterology ,Surgery ,Prednisone ,Internal medicine ,Multicenter trial ,medicine ,Vindesine ,business ,Childhood Acute Lymphoblastic Leukemia ,Teniposide ,medicine.drug - Abstract
In trial ALL-BFM 86, the largest multicenter trial of the Berlin- Frankfurt-Munster (BFM) study group for childhood acute lymphoblastic leukemia (ALL), treatment response was used as an overriding stratification factor for the first time. In the previous trial ALL-BFM 83, the in vivo response to initial prednisone treatment was evaluated prospectively. A blast cell count of > or = 1,000/microL peripheral blood after a 7-day exposure to prednisone and one intrathecal dose of methotrexate (MTX) identified 10% of the patients as having a significantly worse prognosis. In trial ALL-BFM 86 patients with > or = 1,000/microL blood blasts on day 8 were included in an experimental branch EG. Patients with < 1,000/microL blood blasts on day 8 were stratified by their leukemic cell burden into two branches, Standard Risk Group (SRG) and Risk Group (RG). SRG patients received an eight- drug induction followed by consolidation protocol M (6-mercaptopurine, high-dose [HD] MTX 4 x 5 g/m2) and maintenance. RG patients were treated with an additional eight-drug reinduction element. For EG patients protocol M was replaced by protocol E (prednisone, HD-MTX, HD- cytarabine, ifosfamide, mitoxantrone). All patients received intrathecal MTX therapy; only those of branches RG and EG received cranial irradiation. In branch RG, patients were randomized to receive or not to receive late intensification (prednisone, vindesine, teniposide, ifosfamide, HD-cytarabine) in the 13th month. During the trial reinduction therapy was introduced in branch SRG, because in the follow-up of trial ALL-BFM 83 the randomized low-risk patients receiving reinduction did significantly better. Nine hundred ninety- eight evaluable patients were enrolled, 28.6% in SRG, 61.1% in RG, 10.3% in EG. At a median follow-up of 5.0 (range 3.4 to 6.9) years, the estimated 6-year event-free survival was 72% +/- 2% for the study population, 58% +/- 5% in branch SRG for the first 110 patients without reinduction therapy, 87% +/- 3% for the next 175 patients with reinduction therapy, 75% +/- 2% in branch RG, and 48% +/- 5% in branch EG. Late intensification did not significantly affect treatment outcome of RG patients; however, only 23% of the eligible patients were randomized. Prednisone poor response remained a negative prognostic parameter despite intensified therapy. The results confirmed the benefit of intensive reinduction therapy even for low-risk patients. The strategy of induction, consolidation, and intensive reinduction may offer roughly 75% of unselected childhood ALL patients the chance for an event-free survival.
- Published
- 1994
30. Selective targeting of human lymphokine-activated killer cells by CD3 monoclonal antibody against the interferon-inducible high-affinity Fc gamma RI receptor (CD64) on autologous acute myeloid leukemic blast cells
- Author
-
Wolf-Dieter Ludwig, Susanne Bremer, Eckhard Thiel, and Michael Notter
- Subjects
Cytotoxicity, Immunologic ,Adoptive cell transfer ,Immunology ,Fc receptor ,Antigens, CD34 ,chemical and pharmacologic phenomena ,Biochemistry ,Cell Line ,Interferon-gamma ,Antigens, CD ,hemic and lymphatic diseases ,Humans ,Medicine ,Cytotoxic T cell ,Killer Cells, Lymphokine-Activated ,Interleukin 3 ,Lymphokine-activated killer cell ,biology ,business.industry ,Receptors, IgG ,Cell Biology ,Hematology ,Hematopoietic Stem Cells ,Natural killer T cell ,Leukemia, Myeloid, Acute ,biology.protein ,Interleukin 12 ,Cancer research ,CD5 ,business ,Muromonab-CD3 - Abstract
The potential of the CD3 monoclonal antibody (MoAb) OKT3 to selectively target lymphokine-activated killer (LAK) cells and T-cell clones in vitro against autologous tumor cells was studied using material from patients with acute leukemias (19 acute myeloid leukemias [AML], and 3 acute lymphoblastic leukemias [ALL]). Cytotoxicity mediated by patient LAK cells against AML blasts, but not against ALL cells and autologous Epstein-Barr virus-transformed B cells, was enhanced 1.5-fold to 9.3- fold by OKT3 in all AML patients studied. The following findings suggest that the major target molecule on AML cells for OKT3-coated LAK cells is the high-affinity Fc receptor for IgG (Fc gamma RI; CD64): (1) susceptibility to killing by OKT3-coated effector LAK cells segregated with target cell expression of CD64; (2) preincubation of AML blasts with monomeric OKT3 (murine IgG2a), the Fc portion of which is known to have preferential binding affinity to CD64, resulted in lysis by autologous T cells that were not spontaneously cytotoxic; (3) OKT3- dependent increase in lysis of primary and relapsed AML cells by autologous T-cell clones correlated with the amount of target cell expression of CD64; (4) anti-leukemic cytotoxicity of OKT3-coated T cells could partially be inhibited by monomeric human Ig, the natural ligand of CD64; and (5) expression of CD64 (Fc gamma RI) on fresh AML cells could be increased by interferon-gamma (IFN-gamma) and IFN-alpha translating into further enhancement of lysis by autologous OKT3-coated LAK cells. Nonmalignant CD34+ cells sorted from peripheral blood were found to lack expression of CD64 and hence were not affected by OKT3- triggered T-cell targeting, as detected by colony formation assays. In conclusion, the in vitro data presented provide a rationale for the combined clinical use of recombinant interleukin-2, IFN-gamma, and low doses of CD3 MoAb to eliminate AML cells while sparing nonmalignant hematopoietic progenitor cells, for example, in the setting of purging procedures for autologous bone marrow transplantation.
- Published
- 1993
31. CD11b is a therapy resistance- and minimal residual disease-specific marker in precursor B-cell acute lymphoblastic leukemia
- Author
-
Rita Mitlohner, Leonid Karawajew, Giuseppe Basso, Renate Kirschner-Schwabe, Martin Schrappe, Christian Hagemeier, Martin Stanulla, Giuseppe Gaipa, Michael Dworzak, Richard Ratei, Peter Rhein, and Wolf-Dieter Ludwig
- Subjects
Oncology ,Male ,medicine.medical_specialty ,Neoplasm, Residual ,Adolescent ,Immunology ,Antineoplastic Agents ,Biochemistry ,Bone Marrow ,Internal medicine ,Precursor cell ,Precursor B-Cell Lymphoblastic Leukemia-Lymphoma ,medicine ,Biomarkers, Tumor ,Neoplasm ,Humans ,Clinical significance ,Prospective Studies ,RNA, Messenger ,Child ,Survival rate ,Oligonucleotide Array Sequence Analysis ,B-Lymphocytes ,CD11b Antigen ,business.industry ,Reverse Transcriptase Polymerase Chain Reaction ,Gene Expression Profiling ,Remission Induction ,Infant ,Cell Biology ,Hematology ,medicine.disease ,Minimal residual disease ,Gene expression profiling ,Survival Rate ,medicine.anatomical_structure ,Treatment Outcome ,Drug Resistance, Neoplasm ,Child, Preschool ,Female ,Bone marrow ,business ,Burkitt's lymphoma - Abstract
A consistently increased mRNA expression of the adhesion receptor CD11b is a hallmark of the reported genomewide gene expression changes in precursor B-cell acute lymphoblastic leukemia (PBC-ALL) after 1 week of induction therapy. To investigate its clinical relevance, CD11b protein expression in leukemic blasts has been prospectively measured at diagnosis (159 patients) and during therapy (53 patients). The initially heterogeneous expression of CD11b inversely correlated with cytoreduction rates measured at clinically significant time points of induction therapy in the ALL–Berlin-Frankfurt-Münster 2000 protocol. CD11b positivity conferred a 5-fold increased risk of minimal residual disease (MRD) after induction therapy (day 33) and of high-risk group assignment after consolidation therapy (day 78). In the multivariate analysis CD11b expression was an independent prognostic factor compared with other clinically relevant parameters at diagnosis. During therapy, CD11b expression increased early in most ALL cases and remained consistently increased during induction/consolidation therapy. In more than 30% of MRD-positive cases, the CD11b expression on blast cells exceeded that of mature memory B cells and improved the discrimination of residual leukemic cells from regenerating bone marrow. Taken together, CD11b expression has considerable implications for prognosis, treatment response monitoring, and MRD detection in childhood PBC-ALL.
- Published
- 2010
32. Thrombolytic properties of Desmodus rotundus (vampire bat) salivary plasminogen activator in experimental pulmonary embolism in rats
- Author
-
Werner Witt, Linda Cashion, Peter Bringmann, Peter Donner, Berthold Baldus, and Wolf-Dieter Schleuning
- Subjects
Male ,medicine.medical_specialty ,Pathology ,medicine.medical_treatment ,Immunology ,Fibrinogen ,Tissue plasminogen activator ,Biochemistry ,Fibrin ,Plasminogen Activators ,Bolus (medicine) ,Chiroptera ,Internal medicine ,medicine ,Animals ,Thrombolytic Therapy ,Saliva ,alpha-2-Antiplasmin ,biology ,business.industry ,Plasminogen ,Rats, Inbred Strains ,Thrombolysis ,Cell Biology ,Hematology ,biology.organism_classification ,medicine.disease ,Recombinant Proteins ,Rats ,Pulmonary embolism ,Endocrinology ,Tissue Plasminogen Activator ,Desmodus rotundus ,biology.protein ,Pulmonary Embolism ,business ,Plasminogen activator ,medicine.drug - Abstract
rDSPA alpha 1 (recombinant Desmodus salivary plasminogen activator alpha 1) is a recombinant protein corresponding to a natural plasminogen activator from the vampire bat Desmodus rotundus. The thrombolytic properties of rDSPA alpha 1 and tissue-type plasminogen activator (t-PA) were compared in a rat model of pulmonary embolism. Whole blood clots, produced in vitro and labeled with 125I-fibrinogen, were embolized into the lungs of anesthetized rats. Thrombolysis was calculated from the difference between initial clot radioactivity and that remaining in the lungs at 60 minutes. Blood was sampled for gamma counting, measurement of hemostatic factors, and plasminogen activator antigen levels. Thrombolysis at 3, 10, 30, and 100 nmol/kg intravenously (10% bolus, 90% over 60 minutes) amounted to 30% +/- 2%, 51% +/- 4%, 85% +/- 4%, 98% +/- 0% for rDSPA alpha 1 and 30% +/- 3%, 41% +/- 3%, 57% +/- 6%, 93% +/- 2% for t-PA (controls: 29% +/- 2%; mean +/- SEM, n greater than or equal to 6). t-PA at 100 nmol/kg significantly decreased fibrinogen, plasminogen, and alpha 2- antiplasmin levels by 33% +/- 7%, 38% +/- 8%, and 61% +/- 9%, whereas rDSPA alpha 1 at 100 nmol/kg only lowered alpha 2-antiplasmin significantly (by 29% +/- 6%). Compared with t-PA, rDSPA alpha 1 is the more potent and more clot selective (fibrin specific) thrombolytic agent. These results suggest that rDSPA alpha 1 may be safer and more efficacious than currently used thrombolytics.
- Published
- 1992
33. The Addition of Rituximab to CHOP Improves Failure-Free and Overall Survival of Mantle-Cell Lymphoma Patients – a Pooled Trials Analysis of the German Low-Grade Lymphoma Study Group (GLSG)
- Author
-
Hoster, Eva, primary, Unterhalt, Michael, additional, Pfreundschuh, Michael, additional, Hallek, Michael, additional, Forstpointner, Roswitha, additional, Metzner, Bernd, additional, Einsele, Hermann, additional, Krauter, Jürgen, additional, Dührsen, Ulrich, additional, Ludwig, Wolf-Dieter, additional, Birkmann, Josef, additional, Peter, Norma, additional, Klapper, Wolfram, additional, Dreyling, Martin H., additional, and Hiddemann, Wolfgang, additional
- Published
- 2014
- Full Text
- View/download PDF
34. The Strong Prognostic Effect of Concurrent Deletions of IKZF1 and PAX5, CDKN2A, CDKN2B or PAR1 in the Absence of ERG Deletions (IKZF1plus) in Pediatric Acute Lymphoblastic Leukemia Strongly Depends on Minimal Residual Disease Burden after Induction Treatment
- Author
-
Dagdan, Elif, primary, Zaliova, Marketa, additional, Dörge, Petra, additional, Möricke, Anja, additional, Zimmermann, Martin, additional, Teigler-Schlegel, Andrea, additional, Bartram, Claus R, additional, Koehler, Rolf, additional, Ratei, Richard, additional, Ludwig, Wolf-Dieter, additional, Alten, Julia, additional, Schewe, Denis Martin, additional, Kratz, Christian, additional, Houlston, Richard S, additional, Bourquin, Jean-Pierre, additional, Biondi, Andrea, additional, Cazzaniga, Giovanni, additional, Basso, Giuseppe, additional, te Kronnie, Geertruy, additional, Yaspo, Marie-Laure, additional, Schrappe, Martin, additional, Cario, Gunnar, additional, and Stanulla, Martin, additional
- Published
- 2014
- Full Text
- View/download PDF
35. High-resolution genomic profiling of childhood T-ALL reveals frequent copy-number alterations affecting the TGF-beta and PI3K-AKT pathways and deletions at 6q15-16.1 as a genomic marker for unfavorable early treatment response
- Author
-
Martin Schrappe, Stephen Breit, Wiebke Werft, Felix Engel, Bernhard Radlwimmer, Martin Stanulla, Andreas E. Kulozik, Peter Lichter, Marc Remke, Martin Zimmermann, Natalia Becker, Andrea Wittmann, Claus R. Bartram, Shuangyou Liu, Axel Benner, Corinne Kox, Grischa Toedt, Wolf-Dieter Ludwig, Stefan M. Pfister, and Martina U. Muckenthaler
- Subjects
Male ,medicine.medical_specialty ,Adolescent ,Immunology ,Gene Dosage ,Biology ,Precursor T-Cell Lymphoblastic Leukemia-Lymphoma ,Biochemistry ,Gene dosage ,Phosphatidylinositol 3-Kinases ,Gene mapping ,Transforming Growth Factor beta ,Internal medicine ,Antineoplastic Combined Chemotherapy Protocols ,medicine ,Humans ,Multicenter Studies as Topic ,Receptor, Notch1 ,Child ,Gene ,PI3K/AKT/mTOR pathway ,Genetics ,Comparative Genomic Hybridization ,Hematology ,Intracellular Signaling Peptides and Proteins ,Cell Biology ,Prognosis ,Neoplasm Proteins ,Gene expression profiling ,Treatment Outcome ,Child, Preschool ,Cancer research ,CASP8AP2 Gene ,Chromosomes, Human, Pair 6 ,Female ,Chromosome Deletion ,Proto-Oncogene Proteins c-akt ,Cyclin-Dependent Kinase Inhibitor p27 ,Comparative genomic hybridization ,Signal Transduction - Abstract
Precursor T-cell acute lymphoblastic leukemia (T-ALL) in children represents a clinical challenge, because relapses are usually fatal. It is thus necessary to identify high-risk patients as early as possible to effectively individualize treatment. We aimed to define novel molecular risk markers in T-ALL and performed array-based comparative genomic hybridization (array-CGH) and expression analyses in 73 patients. We show that DNA copy-number changes are common in T-ALL and affect 70 of 73 (96%) patients. Notably, genomic imbalances predicted to down-regulate the TGF-β or up-regulate the PI3K-AKT pathways are identified in 25 of 73 (34%) and 21 of 73 (29%) patients, suggesting that these pathways play key roles in T-ALL leukemogenesis. Furthermore, we identified a deletion at 6q15-16.1 in 9 of 73 (12%) of the patients, which predicts poor early treatment response. This deletion includes the CASP8AP2 gene, whose expression is shown to be down-regulated. The interaction of CASP8AP2 with CASP8 plays a crucial role in apoptotic regulation, suggesting a functional link between the clinical effect of the deletion and the molecular mode of action. The data presented here implicate the TGF-β and PI3K-AKT pathways in T-ALL leukemogenesis and identify a subgroup of patients with CASP8AP2 deletions and poor early treatment response.
- Published
- 2009
36. Use of polymerase chain reactions to monitor minimal residual disease in acute lymphoblastic leukemia patients
- Author
-
Anand Raghavachar, Wolf-Dieter Ludwig, T. E. Hansen-Hagge, Claus R. Bartram, Enno Kleihauer, S. Yokota, and Alfred Reiter
- Subjects
Pathology ,medicine.medical_specialty ,business.industry ,T cell ,Immunology ,Cell Biology ,Hematology ,Gene rearrangement ,medicine.disease ,Biochemistry ,Molecular biology ,Minimal residual disease ,law.invention ,Leukemia ,medicine.anatomical_structure ,Maintenance therapy ,law ,Acute lymphocytic leukemia ,medicine ,Bone marrow ,business ,Polymerase chain reaction - Abstract
T-cell receptor (TCR) delta gene rearrangements are observed in more than 80% of acute lymphoblastic leukemia (ALL) patients. Moreover, a preferential usage of specific genetic elements has been shown in different ALL subtypes: V delta 1 DJ delta 1 rearrangements predominate in T-ALL, while most B-precursor ALLs show a recombination of V delta 2 to D delta 3. Recently we have proposed a strategy for the detection of minimal residual disease (MRD) based on the isolation of clonospecific probes following the in vitro amplification of V delta 1 DJ delta 1 junctions by polymerase chain reaction (PCR) and now have adapted this method to the preparation of specific V delta 2 D delta 3 fragments. In the present study, clonospecific probes were generated from 11 T-ALL and 16 cALL patients (21 children, 6 adults). The sensitivity of these 27 probes in detecting residual leukemia cells varied between 10(-4) to 10(-6) as determined by semiquantitative evaluation of dilution experiments. PCR analysis of 55 bone marrow (BM) and peripheral blood (PB) samples obtained from the 27 patients during complete clinical remission showed the following results: (1) Evidence for MRD was obtained in the BM of all patients (eight of eight) investigated 2 to 6 months after remission induction and also in 6 of 11 cases on maintenance therapy 7 to 19 months after diagnosis. (2) In contrast, all patients but one (10 of 11) analyzed 6 to 41 months after the termination of treatment lacked apparent evidence for leukemia DNA; the exception was a girl exhibiting 10(-4) to 10(-5) residual cells in her PB 5.5 years after diagnosis. (3) Longitudinal analysis in nine patients disclosed marked individual differences in the intervals between achievement of clinical remission and complete eradication of the leukemia cell clone. (4) Differences in the duration of MRD were not associated with distinct clinical-hematologic features. (5) Detection of residual disease by PCR proceeded clinical relapse in two cases.
- Published
- 1991
37. Activating NOTCH1 mutations predict favorable early treatment response and long-term outcome in childhood precursor T-cell lymphoblastic leukemia
- Author
-
Martina U. Muckenthaler, Thomas Flohr, Martin Schrappe, Margit Happich, Martin Stanulla, Stephen Breit, Wolf-Dieter Ludwig, Andreas E. Kulozik, and Gabriele Tolle
- Subjects
Oncology ,Male ,medicine.medical_specialty ,Treatment response ,Neoplasm, Residual ,Time Factors ,Adolescent ,Antineoplastic Agents, Hormonal ,Immunology ,Context (language use) ,Biochemistry ,Leukocyte Count ,Immunophenotyping ,Prednisone ,hemic and lymphatic diseases ,Internal medicine ,White blood cell ,Antineoplastic Combined Chemotherapy Protocols ,medicine ,Asparaginase ,Humans ,Receptor, Notch1 ,Receptor ,Child ,business.industry ,Daunorubicin ,Cell Biology ,Hematology ,Precursor Cell Lymphoblastic Leukemia-Lymphoma ,Minimal residual disease ,T-lymphoblastic lymphoma/leukemia ,medicine.anatomical_structure ,Treatment Outcome ,Vincristine ,Child, Preschool ,Mutation ,Female ,business ,Dimerization ,medicine.drug - Abstract
Activating mutations of the transmembrane receptor NOTCH1 are common in precursor T-cell lymphoblastic leukemia (T-ALL). We systematically analyzed the impact of activating NOTCH1 mutations on early treatment response and long-term outcome in 157 patients with T-ALL of the pediatric ALL–Berlin-Frankfurt-Munster (BFM) 2000 study. We confirm previous results that NOTCH1 mutations occur in more than 50% of T-ALL in children. In 82 patients (82/157; 52.2%), activating NOTCH1 mutations were identified either in the heterodimerization (55/82; 67.1%), in the PEST (13/82; 15.9%), or in both domains (14/82; 17.0%). The presence of NOTCH1 mutations was significantly correlated with a good prednisone response and favorable minimal residual disease (MRD) kinetics, which was independent from sex, age, white blood cell count, and T-cell immunophenotype at the time of diagnosis. Furthermore, activating NOTCH1 mutations specified a large subgroup of patients with an excellent prognosis. These findings indicate that in the context of the ALL-BFM 2000 treatment strategy, NOTCH1 mutations predict a more rapid early treatment response and a favorable long-term outcome in children with T-ALL.
- Published
- 2006
38. The Addition of Rituximab to CHOP Improves Failure-Free and Overall Survival of Mantle-Cell Lymphoma Patients – a Pooled Trials Analysis of the German Low-Grade Lymphoma Study Group (GLSG)
- Author
-
Martin Dreyling, Josef Birkmann, Ulrich Dührsen, Eva Hoster, Bernd Metzner, Wolfram Klapper, Hermann Einsele, Michael Pfreundschuh, Wolfgang Hiddemann, Roswitha Forstpointner, Michael Unterhalt, Jürgen Krauter, Norma Peter, Wolf-Dieter Ludwig, and Michael Hallek
- Subjects
Oncology ,medicine.medical_specialty ,Randomization ,business.industry ,Standard treatment ,Immunology ,Hazard ratio ,Cell Biology ,Hematology ,CHOP ,medicine.disease ,Biochemistry ,law.invention ,Surgery ,Autologous stem-cell transplantation ,Randomized controlled trial ,immune system diseases ,law ,hemic and lymphatic diseases ,Internal medicine ,medicine ,Mantle cell lymphoma ,Rituximab ,business ,medicine.drug - Abstract
Introduction: Immunochemotherapy has become the standard of care for patients with mantle-cell lymphoma (MCL) (Dreyling et al., ESMO recommendation for MCL, 2013). Previously, the German Low-Grade Lymphoma Study Group (GLSG) has shown in a randomized trial (GLSG2000) that the addition of rituximab to CHOP improves response rates in untreated advanced stage MCL patients (Lenz et al., JCO 2005). However, the trial was not powered to detect survival differences. Since 1996, patients with MCL have been included in the two consecutive randomized trials GLSG1996 (CHOP vs. MCP, Nickenig et al., Cancer 2006) and GLSG2000. Based on the mature pooled data of these trials we now aimed to compare the long-term clinical outcome of MCL patients treated with CHOP with or without rituximab. Methods: Induction treatment consisted of 4-6 cycles of MCP, CHOP, or R-CHOP. Patients younger than 66 years were subsequently randomized to either myeloablative consolidation and autologous stem cell transplantation, or interferon-alpha maintenance in the first European MCL Trial (Dreyling et al., Blood 2005), whereas older patients were designated to interferon-alpha maintenance. In 1998, randomization between CHOP and MCP (GLSG1996) was stopped due to superior response rates and more effective stem cell mobilization after CHOP, and all subsequently recruited patients were assigned to CHOP. Similarly, in 2002, randomization between CHOP and R-CHOP (GLSG2000) was stopped because of superior response rates after R-CHOP, and all subsequently recruited patients were assigned to R-CHOP. For the current evaluation, we included MCL patients prospectively assigned to either CHOP (GLSG1996 or GLSG2000) or R-CHOP (GLSG2000). We performed an intention-to-treat analysis comparing failure-free (failure: stable disease, progression, or death from any cause) and overall survival (OS) of patients prospectively assigned to R-CHOP versus CHOP, adjusting for potential imbalances in clinical risk profile based on the MIPI score (Hoster et al., JCO 2014). Results: From 1996 to 2004, 386 MCL patients have been prospectively assigned to R-CHOP (185) or CHOP (201). Clinical characteristics were comparable with median age 62 vs. 61 years for R-CHOP vs. CHOP groups, and 40% vs. 42% low risk, 38% vs. 36% intermediate risk, and 22% vs. 21% high risk MIPI. The R-CHOP group showed higher overall response (91% vs. 80%) and complete remission rates (25% vs. 15%). Median failure-free survival was 2.1 compared to 1.4 years (Figure 1, left panel) with adjusted hazard ratio 0.62 (95% CI 0.50-0.78, p Conclusions: After longer follow-up, pooled data of prospective GLSG trials showed prolonged survival by the addition of rituximab to CHOP induction in previously untreated MCL patients. Our results confirm the recommendation for immunochemotherapy as standard treatment for MCL. Compared to previous observations, clinical outcome for MCL patients has improved; however, further improvement by the introduction of more potent chemotherapy (e.g. high-dose cytarabine) or new targeted approaches is urgently warranted. Figure 1: Failure-free (left) and overall survival (right) of patients prospectively assigned to R-CHOP or CHOP in GLSG1996 or GLSG2000 trials Figure 1:. Failure-free (left) and overall survival (right) of patients prospectively assigned to R-CHOP or CHOP in GLSG1996 or GLSG2000 trials Figure 2 Figure 2. Disclosures Hoster: Roche: Travel Support Other. Off Label Use: Rituximab in mantle-cell lymphoma. Unterhalt:Roche: Travel Support Other. Hallek:Roche: Consultancy, Research Funding. Klapper:Roche: Research Funding. Dreyling:Roche: Honoraria, Research Funding. Hiddemann:Roche: Honoraria, Membership on an entity's Board of Directors or advisory committees, Research Funding.
- Published
- 2014
39. The Strong Prognostic Effect of Concurrent Deletions of IKZF1 and PAX5, CDKN2A, CDKN2B or PAR1 in the Absence of ERG Deletions (IKZF1plus) in Pediatric Acute Lymphoblastic Leukemia Strongly Depends on Minimal Residual Disease Burden after Induction Treatment
- Author
-
Rolf Koehler, Denis M. Schewe, Martin Stanulla, Jean-Pierre Bourquin, Marie-Laure Yaspo, Gunnar Cario, Giuseppe Basso, Marketa Zaliova, Anja Möricke, Petra Dörge, Elif Dagdan, Claus R. Bartram, Giovanni Cazzaniga, Andrea Biondi, Geertruy te Kronnie, Richard Ratei, Christian P. Kratz, Andrea Teigler-Schlegel, Martin Schrappe, Julia Alten, Wolf-Dieter Ludwig, Richard S. Houlston, and Martin Zimmermann
- Subjects
Oncology ,medicine.medical_specialty ,Surrogate endpoint ,Immunology ,Hazard ratio ,Cell Biology ,Hematology ,Biology ,Bioinformatics ,Biochemistry ,Minimal residual disease ,ETV6 ,CDKN2A ,Internal medicine ,Cohort ,Clinical endpoint ,medicine ,Cumulative incidence - Abstract
Technical advances in the field of genomic analyses have stimulated a large number of discovery studies on etiological and clinical endpoints in acute lymphoblastic leukemia (ALL) to provide new avenues for preventive strategies, diagnostics and treatment. Recently, deletion of IKZF1 (IKZF1del) was described as a poor prognostic factor in pediatric ALL (Mullighan CG et al., 2012). In our trial AIEOP-BFM ALL 2000 patients with IKZF1del had a lower 5-year event-free survival (EFS; 0.69±0.05 vs. 0.85±0.01; P The present study was undertaken to evaluate the prognostic effect of concurrent recurrent genetic aberrations in association with IKZF1del to further refine a high-risk genetic signature for pediatric ALL treated on AIEOP-BFM protocols. For this purpose, we studied a cohort of 1100 German patients with B-cell precursor ALL treated on AIEOP-BFM ALL 2000 with available characterization of genetic aberrations at initial diagnosis by MLPA (MLPA SALSA kit P335; MRC-Holland) and a PCR assay for detection of ERG deletions (ERGdel; Zaliova M et al., 2014). Validation of results was conducted by use of an independent cohort of 417 Italian patients from the same trial. BCR/ABL1-positive patients were excluded from outcome analysis. When single marker analyses were conducted, IKZF1del was the strongest determinator of outcome in the discovery as well as the validation cohort. When IKZF1del was analyzed in combination with PAX5, CDKN2A, CDKN2B, and PAR1 deletions, patients with an additional deletion to that of IKZF1 had the worst EFS and highest CIR in absence of ERGdel and, consequently, were grouped as IKZF1plus (definition: presence of IKZF1del and at least an additional deletion in PAX5, CDKN2A, CDKN2B or PAR1 in the absence of ERGdel). This group comprised 6% of B-lineage ALL patients and had a very poor clinical outcome: 5y-EFS 50%±0.06 compared to 86%±0.01 in IKZF1plus-negatives (p Newly identified very poor prognostic ALL subgroup – termed IKZF1plus – represented worse outcome compared to that of IKZF1del or others as a sole marker. The differential prognostic effect of IKZF1plus at different MRD levels without currently discernable molecular explanations suggest a quantitative mechanism with higher levels of leukemic cell burden during the early treatment phases predisposing to evolution of a treatment resistant leukemic clone under exposure towards genotoxic chemotherapeutic agents. Potential explanations for these differences in treatment response may be undetected sub-clones already present at diagnosis or underlying germline genetic variation associated with treatment response. Further analyses will be required to better understand this phenomenon. However, due to its strength, the definition of IKZF1plus is likely to aid in the practical implementation of newly detected markers for risk stratification in childhood ALL in a clinical setting. Support: EU FP7 (ENCCA, TRANSCALL), IGA MZ NT/13170-4 Disclosures No relevant conflicts of interest to declare.
- Published
- 2014
40. The impact of the methotrexate administration schedule and dose in the treatment of children and adolescents with B-cell neoplasms: a report of the BFM Group Study NHL-BFM95
- Author
-
Reza Parwaresch, Martin Zimmermann, Norbert Graf, Martin Schrappe, Birgit Burkhardt, Helmut Gadner, Heribert Juergens, Wilhelm Woessmann, Hansjoerg Riehm, Bernd Gruhn, Ilske Oschlies, Wolf-Dieter Ludwig, Thomas Klingebiel, Felix Niggli, Alfred Reiter, Kathrin Seidemann, and Georg Mann
- Subjects
Adult ,Male ,medicine.medical_specialty ,Randomization ,Lymphoma, B-Cell ,Time Factors ,Adolescent ,medicine.drug_class ,Immunology ,Biochemistry ,Antimetabolite ,Gastroenterology ,Disease-Free Survival ,Drug Administration Schedule ,chemistry.chemical_compound ,Internal medicine ,Antineoplastic Combined Chemotherapy Protocols ,medicine ,Mucositis ,Humans ,Child ,Intention-to-treat analysis ,business.industry ,Infant ,Cell Biology ,Hematology ,medicine.disease ,Chemotherapy regimen ,Survival Analysis ,Lymphoma ,Surgery ,Methotrexate ,chemistry ,Child, Preschool ,Antifolate ,Female ,business ,medicine.drug ,Follow-Up Studies - Abstract
In the Non-Hodgkin Lymphoma-Berlin-Frankfurt-Münster 95 (NHL-BFM95) study, we tested by randomization whether for patients with B-cell neoplasms methotrexate as intravenous infusion over 4 hours (MTX-4h) is not inferior to, but less toxic than, a 24-hour intravenous infusion (MTX-24h). Second, we investigated against the historical control of study NHL-BFM90, whether for patients with moderate tumor mass MTX can be reduced from 5 g/m(2) to 1 g/m(2). Patients received 2 5-day therapy courses in risk group R1 (resected), 4 in R2 (lactate dehydrogenase [LDH]500 U/L), 5 in R3 (LDH500 to1000 U/L) and 6 in R4 (LDH1000 U/L and/or central nervous system [CNS] disease). Courses contained MTX 1 g/m(2) in R1 + R2 and 5 g/m(2) in R3 + R4. Of 505 patients (April 1996 to March 2001), 364 were randomized to receive MTX-4h or MTX-24h. Failure-free survival (pFFS, 1 year) for arm MTX-4h versus MTX-24h, respectively, was 95% +/- 5% (n = 20) versus 100% (n = 19) in R1, 94% +/- 2% (n = 88) versus 96% +/- 2% (n = 95) in R2, and 77% +/- 5% (n = 62) versus 93% +/- 3% (n = 69) in R3 +/- R4 (per-protocol analysis). Incidence of mucositis grade III/IV was significantly lower with MTX-4h in all risk groups. For patients in R2, event-free survival (pEFS) was 95% +/- 2% (n = 222) in NHL-BFM95 (MTX 1 g/m(2)) and 97% +/- 1% (n = 154) in NHL-BFM90 (MTX 5 g/m(2)). In conclusion, MTX-4h was less toxic than MTX-24h. MTX-4h was noninferior to MTX-24h for limited stage B-cell non-Hodgkin lymphoma (B-NHL) but not for advanced disease. For limited disease, MTX 1 g/m(2) is noninferior to 5 g/m(2).
- Published
- 2004
41. High Efficacy and Significantly Shortened Neutropenia Of Dose-Dense S-HAM As Compared To Standard Double Induction: First Results Of a Prospective Randomized Trial (AML-CG 2008)
- Author
-
Braess, Jan, primary, Kreuzer, Karl-Anton, additional, Spiekermann, Karsten, additional, Lindemann, Hans Walter, additional, Lengfelder, Eva, additional, Graeven, Ullrich, additional, Staib, Peter, additional, Ludwig, Wolf-Dieter, additional, Biersack, Harald, additional, Ko, Yon-Dschun, additional, Uppenkamp, Michael J., additional, Korsten, Stefan, additional, De Wit, Maike, additional, Peceny, Rudolf, additional, Gaska, Tobias, additional, Schiel, Xaver, additional, Behringer, Dirk M, additional, Kiehl, Michael G., additional, Zinngrebe, Bettina, additional, Meckenstock, Gerald, additional, Roemer, Eva, additional, Medgenberg, Dirk, additional, Spaeth-Schwalbe, Ernst, additional, Braess, Birgit, additional, Massenkeil, Gero, additional, Hindahl, Heidrun, additional, Trenn, Guido, additional, Schwerdtfeger, Rainer, additional, Amler, Susanne, additional, Sauerland, Cristina, additional, Faldum, Andreas, additional, Unterhalt, Michael, additional, Bohlander, Stefan K., additional, Schneider, Stephanie, additional, Dufour, Annika, additional, Buske, Christian, additional, Fiegl, Michael, additional, Subklewe, Marion, additional, Baumgartner, Anja, additional, Woermann, Bernhard J., additional, Beelen, Dietrich, additional, and Hiddemann, Wolfgang, additional
- Published
- 2013
- Full Text
- View/download PDF
42. In vitro susceptibility to dexamethasone- and doxorubicin-induced apoptotic cell death in context of maturation stage, responsiveness to interleukin 7, and early cytoreduction in vivo in childhood T-cell acute lymphoblastic leukemia
- Author
-
Wolf-Dieter Ludwig, Bernd Dörken, Martin Schrappe, Christian Wuchter, Leonid Karawajew, and V. Ruppert
- Subjects
Immunology ,Sialic Acid Binding Ig-like Lectin 3 ,CD2 Antigens ,Antigens, Differentiation, Myelomonocytic ,Antigens, CD34 ,Apoptosis ,Biochemistry ,Dexamethasone ,Immunophenotyping ,Antigens, CD1 ,In vivo ,Antigens, CD ,Acute lymphocytic leukemia ,Tumor Cells, Cultured ,Medicine ,Humans ,Child ,Childhood Acute Lymphoblastic Leukemia ,Neoplasm Staging ,business.industry ,Interleukin-7 ,Interleukin ,Cell Biology ,Hematology ,Precursor Cell Lymphoblastic Leukemia-Lymphoma ,Fas receptor ,medicine.disease ,Doxorubicin ,Drug Resistance, Neoplasm ,Cancer research ,business ,medicine.drug - Abstract
Within childhood T-cell acute lymphoblastic leukemia (T-ALL), patients with a cortical (CD1a+) immunophenotype have been identified as a subgroup with favorable outcome in the acute lymphoblastic leukemia–Berlin-Frankfurt-Münster (ALL-BFM), Cooperative study group for childhood acute lymphoblastic leukemia (COALL) and Pediatric Oncology Group studies. We investigated in leukemic samples of children with T-ALL (n = 81) whether the different in vivo therapy response could be linked to differential in vitro susceptibility to apoptotic cell death. The extent of dexamethasone- as well as doxorubicin-induced apoptosis, detected by annexin V staining, positively correlated with the expression levels of CD1a (Spearman correlation coefficient, rs = 0.3 and 0.4, respectively; P
- Published
- 2002
43. High Efficacy and Significantly Shortened Neutropenia Of Dose-Dense S-HAM As Compared To Standard Double Induction: First Results Of a Prospective Randomized Trial (AML-CG 2008)
- Author
-
Dirk Medgenberg, Anja Baumgartner, Guido Trenn, Ernst Spaeth-Schwalbe, Gerald Meckenstock, Stefan Korsten, Michael Uppenkamp, Jan Braess, Rudolf Peceny, Birgit Braess, Yon-Dschun Ko, Harald Biersack, Dietrich W. Beelen, Xaver Schiel, E. Roemer, Heidrun Hindahl, Annika Dufour, Maike de Wit, Peter Staib, Karsten Spiekermann, Marion Subklewe, Rainer Schwerdtfeger, Wolf-Dieter Ludwig, Cristina Sauerland, Wolfgang Hiddemann, Gero Massenkeil, Stefan K. Bohlander, Christian Buske, Susanne Amler, Michael G. Kiehl, Ullrich Graeven, Michael Fiegl, Michael Unterhalt, Karl-Anton Kreuzer, Eva Lengfelder, Bettina Zinngrebe, Bernhard J. Woermann, Hans Walter Lindemann, Andreas Faldum, Dirk Behringer, Tobias Gaska, and Stephanie Schneider
- Subjects
Mitoxantrone ,medicine.medical_specialty ,Chemotherapy ,business.industry ,medicine.medical_treatment ,Immunology ,Induction chemotherapy ,Cell Biology ,Hematology ,Neutropenia ,medicine.disease ,Biochemistry ,law.invention ,Regimen ,Randomized controlled trial ,law ,Internal medicine ,medicine ,Clinical endpoint ,Cytarabine ,business ,medicine.drug - Abstract
Background For curative treatment of younger patients with acute myeloid leukemia (AML) double induction with two cycles of intensive cytarabine/ anthracycline based chemotherapy 21 days apart is the current standard of care. In the prospective randomized AML-CG 2008 trial we asked question whether current results could be improved on by a dose-dense regimen (S-HAM – Sequential High-dose cytArabine and Mitoxantrone) in which the interval between cycles was minimized to 3 days. A prior large one-armed study (AML-CG 2004) had demonstrated a high antileukemic efficacy and shortened neutropenia of the S-HAM regimen as compared to a historical control of standard double induction treatment. The first clinical results of the randomized comparison are presented here. Methods All patients with first diagnosis of a de-novo or secondary AML (excluding APL) that were deemed fit for intensive induction chemotherapy by their treating physician were eligible for this study. Younger patients in the standard arm were treated with one cycle of TAD-9 (standard dose cytarabine and daunorubicine 60mg/m2 for 3 days) and a mandatory second cycle of HAM (high dose cytarabine and mitoxantrone) starting at day 21. Elderly patients were treated with one cycle of HAM followed by a second cycle of HAM only in case of residual leukemia in the day 16 bone marrow aspirate. Patients in the experimental arm all received S-HAM (two sequential cycles of high-dose cytarabine on days 1+2, mitoxantrone days 3+4) with a 3 days interval. Patients in the age cohort 60 – 69 could be allocated to the “younger” or “elderly” cohort according to their biological fitness at the discretion of the treating physician. However high-dose cytarabine dosages were allocated according to chronological age with patients Results 396 patients were randomized into the study with an age range of 18 to 86 years (median 58). The 387 evaluable patients (184 standard, 203 experimental) were well balanced according to their clinical characteristics, cytogenetics, molecular genetics and overall risk profile. For the primary endpoint a higher ORR of 77% for S-HAM could be found as compared to 72% in the standard arm which was however not significant because a 15% difference had been postulated for the study. Non-hematological toxicities did not show any significant differences. However this was in clear contrast to hematological toxicities: Importantly the duration of critical neutropenia was highly significantly reduced by more than 2 weeks from 45 days (standard) to 29 days (S-HAM) counted from day 1 of treatment. Similarly critical thrombocytopenia was reduced by 13 days from 46 days to 33 days. The early death (ED) rate between both arms was identical between both arms. However a subgroup analysis demonstrated a significantly reduced ED rate in patients receiving 1g/m2 S-HAM as compared to all other treatment groups. The respective ED rates for the various time intervals (always counted from day d1 of treatment) for the 1g/m2S-HAM group were as follows: Interval d1-14 1%, d1-30 3%, d1-60 5%, d1-90 10%. Data for overall survival will be available in November 2013. Conclusion The dose-dense induction regimen S-HAM was highly feasible in patients up to the 8th age decade. The antileukemic efficacy was high with an ORR of 77% for the whole group of unselected patients. As compared to standard double induction dose-dense S-HAM reduced critical neutropenia by more than two weeks. Moreover the subgroup of patients receiving the 1g/m2 S-HAM regimen experienced the lowest ED rate ever reported in the AML-CG trials. This underlines that in contrast to our general expectations the concept of dose-density is able to combine high antileukemic efficacy with significantly reduced haematological toxicity in AML, characterising this approach as first candidate for the next standard arm for future trials of the study group. Disclosures: Lengfelder: TEVA/ Cephalon: Research Funding.
- Published
- 2013
44. Prednisone response is the strongest predictor of treatment outcome in infant acute lymphoblastic leukemia
- Author
-
Alfred Reiter, Martin Schrappe, Wolf-Dieter Ludwig, Helmut Gadner, Hansjörg Riehm, Arndt Borkhardt, Susanne Viehmann, Nicolai Götz, and Michael Dördelmann
- Subjects
Male ,medicine.medical_specialty ,Antineoplastic Agents, Hormonal ,medicine.drug_class ,medicine.medical_treatment ,Immunology ,Biochemistry ,Gastroenterology ,Disease-Free Survival ,Prednisone ,Predictive Value of Tests ,Internal medicine ,White blood cell ,Acute lymphocytic leukemia ,Antineoplastic Combined Chemotherapy Protocols ,medicine ,Humans ,Child ,Retrospective Studies ,Chemotherapy ,Univariate analysis ,business.industry ,Infant ,Cell Biology ,Hematology ,Precursor Cell Lymphoblastic Leukemia-Lymphoma ,medicine.disease ,Prognosis ,Infant Acute Lymphoblastic Leukemia ,Surgery ,medicine.anatomical_structure ,Child, Preschool ,Multivariate Analysis ,Corticosteroid ,Methotrexate ,Female ,business ,medicine.drug - Abstract
To define prognostic factors in infant acute lymphoblastic leukemia (ALL), the outcome of 106 infants (age ≤12 months) during 3 consecutive multicenter trials of the Berlin-Frankfurt-Münster group (ALL-BFM 83, 86, and 90) was retrospectively analyzed according to presenting features and early in vivo response to prednisone. The prednisone response was defined as the cytoreduction (number of blood blasts per microliter at day 8) to a 7-day prednisone prephase and 1 intrathecal dose of methotrexate on day 1. Prednisone good responder (PGR
- Published
- 1999
45. Intact apoptosis signaling in myeloid leukemia cells determines treatment outcome in childhood AML
- Author
-
Meyer, Lüder H., Queudeville, Manon, Eckhoff, Sarah M., Creutzig, Ursula, Reinhardt, Dirk, Karawajew, Leonid, Ludwig, Wolf-Dieter, Stahnke, Karsten, and Debatin, Klaus-Michael
- Published
- 2008
- Full Text
- View/download PDF
46. Clinical features and outcome of children with first marrow relapse of acute lymphoblastic leukemia expressing BCR-ABL fusion transcripts. BFM Relapse Study Group
- Author
-
Birgit Beyermann, C Linderkamp, Günter Henze, Hans-Peter Adams, G Goetze, Karlheinz Seeger, Wolf-Dieter Ludwig, and AG Agthe
- Subjects
Oncology ,Male ,medicine.medical_specialty ,Adolescent ,Immunology ,Molecular Sequence Data ,Fusion Proteins, bcr-abl ,Gene Expression ,Philadelphia chromosome ,Biochemistry ,hemic and lymphatic diseases ,Acute lymphocytic leukemia ,White blood cell ,Internal medicine ,Leukemia, Myelogenous, Chronic, BCR-ABL Positive ,medicine ,Humans ,Prospective Studies ,RNA, Messenger ,Prospective cohort study ,Child ,Survival analysis ,DNA Primers ,Base Sequence ,business.industry ,Incidence (epidemiology) ,Infant ,Cell Biology ,Hematology ,Precursor Cell Lymphoblastic Leukemia-Lymphoma ,medicine.disease ,Prognosis ,Survival Analysis ,Gene Expression Regulation, Neoplastic ,medicine.anatomical_structure ,El Niño ,Child, Preschool ,Female ,Bone marrow ,business - Abstract
Although the Philadelphia chromosome (Ph1) has been identified as an adverse prognostic factor in acute lymphoblastic leukemia (ALL), little is known about the incidence and clinical course of relapsed Ph1- positive ALL in children. The incidence was determined by screening of 170 consecutive children with first bone marrow relapse of ALL using the reverse transcriptase-polymerase chain reaction (RT-PCR) and comparison, with cytogenetic analysis. Among these 170 children, 20 (12%) were found to be BCR-ABL-positive, representing a rate that is about three times higher than that reported for newly diagnosed ALL. Ten of the cases were identified by RT-PCR only. In none of the 21 patients with T-cell immunophenotypes could an expression of the BCR- ABL mRNA be detected. BCR-ABL positivity was associated with a significantly shorter duration of first remission (P = .0086) and higher white blood cell (P = .0157) and blast cell counts (P = .0304) at relapse diagnosis. All patients were treated according to the ALL- REZ BFM 87 and 90 relapse trials of the BFM Relapse Study Group. The intensive multiagent chemotherapy induced a second complete remission in only 60% of children with BCR-ABL-positive ALL compared with in 91% of those without BCR-ABL expression (P = .0023). The prognosis of BCR- ABL-positive ALL in children is poor, with a probability of event-free survival at 2 years of 8% versus 50% in those without BCR-ABL mRNA or cytogenetic analysis should become part of the routine diagnostic panel for children with newly diagnosed ALL and is fundamental for children presenting with an early bone marrow relapse.
- Published
- 1996
47. Improved outcome in adult B-cell acute lymphoblastic leukemia
- Author
-
D. K. Hossfeld, Georg Maschmeyer, I. Strohscheer, C. Schadeck-Gressel, C. Fonatsch, B. Völkers, Martin Gramatzki, Gerhard Heil, U. Fabry, Wolf-Dieter Ludwig, Harald Rieder, T. Büchner, R. Kuse, M. Freund, B. Heinze, Renate Arnold, P. Koch, Axel Heyll, A. Weiss, Karl Überla, H. Löffler, E. Thiel, Wolfgang Hiddemann, Thomas Faak, W. Gassmann, Karin Kolbe, H. G. Fuhr, Carlo Aul, Bernd Metzner, Nicola Gökbuget, Dieter Hoelzer, Thomas Ittel, K. Fischer, D. Messerer, and H. Diedrich
- Subjects
Male ,Gastrointestinal Diseases ,medicine.medical_treatment ,Biochemistry ,Gastroenterology ,Dexamethasone ,Meninges ,Antineoplastic Combined Chemotherapy Protocols ,Bone Marrow Diseases ,Bone Marrow Transplantation ,Remission Induction ,Cytarabine ,Hematology ,Middle Aged ,Burkitt Lymphoma ,Combined Modality Therapy ,Survival Rate ,Treatment Outcome ,Vincristine ,Female ,medicine.drug ,Adult ,medicine.medical_specialty ,Cyclophosphamide ,Adolescent ,Immunology ,Disease-Free Survival ,Leukemic Infiltration ,Internal medicine ,Acute lymphocytic leukemia ,medicine ,Humans ,Ifosfamide ,Survival rate ,Aged ,Teniposide ,Chemotherapy ,Stomatitis ,business.industry ,Cell Biology ,medicine.disease ,Survival Analysis ,Surgery ,Methotrexate ,Doxorubicin ,Prednisone ,Cranial Irradiation ,business - Abstract
A total of 68 adult patients with B-cell acute lymphoblastic leukemia (B-ALL) were treated in three consecutive adult multicenter ALL studies. The diagnosis of B-ALL was confirmed by L3 morphology and/or by surface immunoglobulin (Slg) expression with > 25% blast cell infiltration in the bone marrow (BM). They were characterized by male predominance (78%) and a median age of 34 years (15 to 65 y) with only 9% adolescents (15 to 20 y), but 28% elderly patients (50 to 65 y). The patients received either a conventional (N = 9) ALL treatment regimen (ALL study 01/81) or protocols adapted from childhood B-ALL with six short, intensive 5-day cycles, alternately A and B. In study B-NHL83 (N = 24) cycle A consisted of fractionated doses of cyclophosphamide 200 mg/m2 for 5 days, intermediate-dose methotrexate (IdM) 500 mg/m2 (24 hours), in addition to cytarabine (AraC), teniposide (VM26) and prednisone. Cycle B was similar except that AraC and VM26 were replaced by doxorubicin. Major changes in study B-NHL86 (N = 35) were replacement of cyclophosphamide by ifosphamide 800 mg/m2 for 5 days, an increase of IdM to high-dose, 1,500 mg/m2 (HdM) and the addition of vincristine. A cytoreductive pretreatment with cyclophosphamide 200 mg/m2, and prednisone 60 mg/m2, each for 5 days was recommended in study B-NHL83 for patients with high white blood cell (WBC) count (e 2,500/m2) or large tumor burden and was obligatory for all patients in study B-NHL86. Central nervous system (CNS) prophylaxis/treatment consisted of intrathecal methotrexate (MTX) therapy, later extended to the triple combination of MTX, AraC, and dexamethasone, and a CNS irradiation (24 Gy) after the second cycle. Compared with the ALL 01/81 study where all the patients died, results obtained with the pediatric protocols B-NHL83 and B-NHL86 were greatly improved. The complete remission (CR) rates increased from 44% to 63% and 74%, the probability of leukemia free survival (LFS) from 0% to 50% and 71% (P = .04), and the overall survival rates from 0% to 49% and 51% (P = .001). Toxicity, mostly hematotoxicity and mucositis, was severe but manageable. In both studies B-NHL83 and B-NHL86, almost all relapses occurred within 1 year. The time to relapse was different for BM, 92 days, and for isolated CNS and combined BM and CNS relapses, 190 days (P = .08). The overall CNS relapses changed from 50% to 57% and 17%, most probably attributable to the high-dose MTX and the triple intrathecal therapy. LFS in studies B-NHL83 and B-NHL86 was significantly influenced by the initial WBC count < or > 50,000/microL, LFS 71% versus 29% (P = .003) and hemoglobin value > or < 8 g/dL, LFS 67% versus 27% (P = .02). Initial CNS involvement had no adverse impact on the outcome. Elderly B- ALL patients (> 50 years) also benefited from this treatment with a CR rate of 56% and a LFS of 56%. It is concluded that this short intensive therapy with six cycles is effective in adult B-ALL. HdM and fractionated higher doses of cyclophosphamide or ifosphamide seem the two major components of treatment.
- Published
- 1996
48. Prolonged Remission Duration with Interferon Maintenance After Rituximab-Containing Induction in First-Line Advanced Stage Lymphoplasmacytic Lymphoma – a Retrospective Analysis of the German Low-Grade Lymphoma Study Group (GLSG)
- Author
-
Hoster, Eva, primary, Unterhalt, Michael, additional, Metzner, Bernd, additional, Pfreundschuh, Michael, additional, Staib, Peter, additional, Jacobs, Georg, additional, Lindemann, Hans Walter, additional, Ludwig, Wolf-Dieter, additional, Steinmetz, H. Tilman, additional, Truemper, Lorenz, additional, Wandt, Hannes, additional, Buske, Christian, additional, Dreyling, Martin H., additional, and Hiddemann, Wolfgang, additional
- Published
- 2011
- Full Text
- View/download PDF
49. Outcome of Myelodysplastic Syndrome Treated with Intensive Chemotherapy within the AMLCG99 Trial
- Author
-
Krug, Utz, primary, Muller-Tidow, Carsten, additional, Stelljes, Matthias, additional, Sauerland, Maria Cristina, additional, Heinecke, Achim, additional, Haferlach, Claudia, additional, Schnittger, Susanne, additional, Haferlach, Torsten, additional, Braess, Jan, additional, Spiekermann, Karsten, additional, Volpert, Sarah, additional, Staib, Peter, additional, Grüneisen, Andreas, additional, Kern, Wolfgang, additional, Reichle, Albrecht, additional, Ludwig, Wolf-Dieter, additional, Balleisen, Leopold, additional, Eimermacher, Hartmut, additional, Aul, Carlo, additional, Rasche, Herbert, additional, Lengfelder, Eva, additional, Thiel, Eckhard, additional, Kienast, Joachim, additional, Serve, Hubert, additional, Woermann, Bernhard Josef, additional, Hiddemann, Wolfgang, additional, Berdel, Wolfgang E., additional, and Buchner, Thomas, additional
- Published
- 2011
- Full Text
- View/download PDF
50. Intermediate-Risk Acute Lymphoblastic Leukemia (ALL) Patients with and without Relapse Differentially Depend on Survival Signals From Microenvironment
- Author
-
Rhein, Peter, primary, Mitlohner, Rita, additional, Kirschner-Schwabe, Renate, additional, Hagemeier, Christian, additional, Cario, Gunnar, additional, Stanulla, Martin, additional, Schrappe, Martin, additional, Fichtner, Iduna, additional, Ratei, Richard, additional, Ludwig, Wolf-Dieter, additional, and Karawajew, Leonid, additional
- Published
- 2011
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.